The Wolf lab focuses on the characterization of the effective and failing T cell receptor (TCR)-repertoire to identify therapeutic TCR candidates for potential clinical translation. The gained insights can be applied to various immunotherapies since our research investigates the TCR-response of the host, which is the foundation to understand and utilize an effective immune response against any target.
We study pre-clinical mouse models as well as human patient samples to translate findings from bench to bedside and back again. Current human cancers of interest are high-grade serous ovarian carcinoma, colorectal cancer, and acute myeloid leukemia. The main aim is advancing individualized TCR-T cell therapy against any type of cancer. To achieve this, the long-term goal is building a platform that allows the selection and validation of putative therapeutic TCR candidates. However, insights will also improve our understanding of various other immunotherapeutic interventions using vaccinations, tumor infiltrating lymphocytes (TILs) or immune checkpoint blockade (ICB).
Our mouse models focus mainly on CD4+ T cells either alone or in combination with CD8+ T cells. We have a strong interest in the interaction of T cells with the cellularly and molecularly complex tumor microenvironment.
The University of Chicago
Chicago, USA
Postdoc - Immunotherapy
2023
Freie University Berlin
Berlin, Germany
Ph.D. - Cancer Immunology
2020
Johannes Gutenberg University
Mainz, Germany
Diploma - Biomedical Chemistry
2014
Mapping the TCR landscape: computational tools empowering translational immunology and therapy design.
Mapping the TCR landscape: computational tools empowering translational immunology and therapy design. J Immunother Cancer. 2026 Jun 18; 14(6).
PMID: 42315254
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases.
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases. Oncoimmunology. 2025 Dec; 14(1):2514041.
PMID: 40515594
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire.
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire. J Immunother Cancer. 2025 May 02; 13(5).
PMID: 40316304
CD4+ T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy.
CD4+ T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy. Sci Immunol. 2024 09 13; 9(99):eadp6529.
PMID: 39270007
One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication.
One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication. Clin Cancer Res. 2024 Apr 15; 30(8):1642-1654.
PMID: 38190111
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model. J Immunother Cancer. 2023 05; 11(5).
PMID: 37258040
Criteria to make animal studies more relevant to treating human cancer.
Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2022 02; 74:25-31.
PMID: 34619458
Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens.
Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. Carcinogenesis. 2020 11 13; 41(11):1605-1615.
PMID: 32221533
Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides.
Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides. Proc Natl Acad Sci U S A. 2020 06 30; 117(26):15148-15159.
PMID: 32541028
Automated cell cluster analysis provides insight into multi-cell-type interactions between immune cells and their targets.
Automated cell cluster analysis provides insight into multi-cell-type interactions between immune cells and their targets. Exp Cell Res. 2020 08 15; 393(2):112014.
PMID: 32439494